Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives Consensus Rating of “Reduce” from Analysts

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) have received an average rating of “Reduce” from the seven analysts that are currently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $14.80.

Several research analysts have weighed in on IART shares. Wells Fargo & Company lowered their target price on shares of Integra LifeSciences from $13.00 to $12.00 and set an “equal weight” rating for the company in a research note on Friday, February 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Monday, December 29th. Finally, Wall Street Zen lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Saturday.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in IART. Rubric Capital Management LP grew its stake in Integra LifeSciences by 1.3% during the 4th quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock worth $96,304,000 after purchasing an additional 100,000 shares in the last quarter. Invesco Ltd. raised its position in Integra LifeSciences by 0.9% in the 4th quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock valued at $43,754,000 after purchasing an additional 31,931 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Integra LifeSciences by 9.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock valued at $45,634,000 after purchasing an additional 267,134 shares in the last quarter. State Street Corp boosted its stake in shares of Integra LifeSciences by 0.8% in the 4th quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock valued at $34,933,000 after buying an additional 21,717 shares during the period. Finally, Paradigm Capital Management Inc. NY grew its position in shares of Integra LifeSciences by 5.3% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 2,664,998 shares of the life sciences company’s stock worth $33,099,000 after buying an additional 135,198 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Price Performance

NASDAQ:IART opened at $9.73 on Monday. Integra LifeSciences has a 52 week low of $9.36 and a 52 week high of $24.36. The company has a quick ratio of 1.46, a current ratio of 2.54 and a debt-to-equity ratio of 1.66. The company has a market capitalization of $758.33 million, a P/E ratio of -1.45 and a beta of 1.02. The stock’s fifty day moving average is $11.72 and its two-hundred day moving average is $13.04.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.04. The business had revenue of $434.93 million during the quarter, compared to analysts’ expectations of $429.62 million. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The company’s revenue was down 1.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.97 EPS. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Equities analysts expect that Integra LifeSciences will post 2.45 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.